Merck Sharp & Dohme LLC has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis ...
In fact, a solid body of research findings suggests that CWP may be a neglected risk factor for CVD. Atherosclerosis, a key contributor to CVD, is a chronic inflammatory disease that changes the ...